N-Acetylcysteine in Severe Acute Alcoholic Hepatitis - Full Text View

Purpose

Acute alcoholic hepatitis (AAH) is the most severe form of alcoholic liver disease (ALD) and is associated with a high risk of dying in the short term. Corticosteroids are generally recommended in patients with severe AAH, but its use is still controverted and contraindicated in case of active infection or gastrointestinal bleeding. Therefore, alternative therapeutic options are needed.Ethanol consumption results in the depletion of endogenous antioxidant capabilities and patients with ALD have evidence of antioxidant deficiencies.Due to its effects on glutathion stores restoration and as such the limitation of the oxidative stress and its good tolerance and safety profile, N-acetylcysteine (NAC) is an attractive agent for the treatment of AAH.In this context, we hypothesized that NAC might be beneficial in severe AAH.

Condition	Intervention	Phase
Alcoholic Hepatitis	Drug: N-Acetylcysteine Drug: placebo	Phase 3


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	N-Acetylcysteine for the Treatment of Alcoholic Hepatitis: a Belgian Multicenter Randomised Trial

Resource links provided by NLM:

MedlinePlus related topics: Hepatitis Hepatitis A

Drug Information available for: Acetylcysteine

U.S. FDA Resources

Further study details as provided by Erasme University Hospital:

Primary Outcome Measures:

Six months survival [ Designated as safety issue: No ]

Secondary Outcome Measures:

Rate of infections, clinical and biological parameters [ Designated as safety issue: Yes ]


Enrollment:	44
Study Start Date:	September 2000
Primary Completion Date:	January 2006 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: nutritional support + N-Acétylcysteine N-Acétylcysteine 300 mg/kg intravenously for 14 days Beside usual meals, patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days	Drug: N-Acetylcysteine 300 mg/kg for 14 days, intravenously
Placebo Comparator: nutritional support + placebo placebo perfusion for 14 days Beside usual meals patients must receive at least 27 kcal/kg/day enteral nutrition for 14 days	Drug: placebo Glucosé 5% perfusion for 14 days, intravenously

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Biopsy proven alcoholic hepatitis
Severe disease defined by a Maddrey score superior to 32

Exclusion Criteria:

Neoplastic disease compromising 6 months survival
HIV patients
Hepatorenal syndrome

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00962442

Locations


Belgium
Erasme University Hospital
Brussels, Belgium, 1070

Sponsors and Collaborators

Erasme University Hospital

More Information


Responsible Party:	Olivier Le Moine, MD, PhD, Erasme University Hospital
ClinicalTrials.gov Identifier:	NCT00962442 History of Changes
Other Study ID Numbers:	AAH-LYSO
Study First Received:	August 19, 2009
Last Updated:	August 19, 2009
Health Authority:	Belgium: Institutional Review Board

Keywords provided by Erasme University Hospital:


alcoholic hepatitis N-Acetylcysteine enteral nutrition oxidative stress severe acute alcoholic hepatitis

Additional relevant MeSH terms:


Hepatitis, Alcoholic Hepatitis Hepatitis A Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections Liver Diseases, Alcoholic Alcohol-Induced Disorders Alcohol-Related Disorders Substance-Related Disorders	Chemically-Induced Disorders Acetylcysteine N-monoacetylcystine Antiviral Agents Anti-Infective Agents Expectorants Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Antidotes

ClinicalTrials.gov processed this record on September 28, 2016